動脈硬化対策の最近の進展と将来の治療目標
Zhongmin Wang1, Xiao He1, Huayang Bai1
1Chongqing Key Laboratory of Medicinal Chemistry and Molecular Pharmacology, Chongqing University of Technology, Chongqing 400054, China.
International journal of pharmaceutics
|August 31, 2025
まとめ
このレビューでは,小分子,PCSK9阻害剤などのマクロ分子,およびナノ医薬品を含む高度な動脈硬化症の治療法を調査しています. この困難な心臓血管疾患の管理のための革新的な戦略を強調しています.
科学分野:
- 心血管医学
- 薬理学について
- ナノテクノロジー
背景:
- 動脈硬化には脂質の蓄積とプラーク形成があり,動脈狭窄につながる.
- 現在の治療法では 進行を制御できますが 治療はできません
- 生物医学における進歩は 動脈硬化症の新たな治療方法を必要とします
研究 の 目的:
- 動脈硬化症の治療における最近の進歩を体系的に検討する.
- 小分子薬,マクロ分子療法,ナノ医療をカバーする.
- 動脈硬化症の革新的な治療法の可能性と課題について議論する.
主な方法:
- 小分子薬 (タンパク質標的阻害剤/アゴニスト,天然化合物) の文献レビュー
- プロプロテインコンバーターゼサブチリシン/ケキシン9型 (PCSK9) 阻害剤に焦点を当てたマクロ分子薬のレビュー.
- ナノ医療の応用と相乗効果の分析
主要な成果:
- 小さな分子はタンパク質標的の調節と 自然化合物を利用する.
- マクロ分子戦略には,高度なPCSK9阻害剤が含まれています.
- ナノ医療は 連携効果と革新的な治療法を 提供しています
結論:
- 最近の戦略は 動脈硬化症の管理に有望です
- 新しい治療法を臨床実践に 導入する際には 課題が残っています
- 革新的なデザインコンセプトは 将来の動脈硬化症治療の開発に不可欠です
さらに関連する動画
関連する概念動画
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:23Atherosclerosis IV: Nursing Management
50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
01:30Atherosclerosis I: Introduction
76
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
76
01:27Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505